Definitive radiotherapy and Single-Agent radiosensitizing Ifosfamide in Patients with localized, irresectable Soft Tissue Sarcoma: A retrospective analysis

Background and Purpose: Standard therapy for soft-tissue sarcomas
remains complete resection. For primary radiotherapy local control
rates of 30-45% have been reported. We analyzed retrospectively 11
cases of radiochemotherapy with single-agent ifosfamide in patients
with macroscopic soft-tissue sarcomas. Patients and Methods: The
patients were treated in irresectable high risk situations.
Radiation therapy was performed with median 60 Gy. During the first
and fifth week the concomitant chemotherapy with ifosfamide was
added. Two patients received trimodal therapy with additional
regional hyperthermia. Results: The therapy was completed in 73% of
the patients. Average local control time was 91 months, median
disease-free-survival/overall-survival was 8/26 months. Five-year
rates for local control/disease free survival/overall survival were
70%/34%/34%. The limited prognosis is mainly caused by systemic
treatment failure. Conclusions: The data strongly suggest a better
outcome of radiochemotherapy with ifosfamide compared to
radiotherapy alone and radiotherapy in combination with other
radiosensitizers.